Terms: = Pancreatic cancer AND DAXX, BING2, 1616, ENSG00000206206, MGC126246, Q9UER7, MGC126245, DAQB-126H3_2, DAP6 AND Treatment
12454 results:
1. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification.
Huai M; Wang Y; Li J; Pan J; Sun F; Zhang F; Zhang Y; Xu L
J Nanobiotechnology; 2024 May; 22(1):257. PubMed ID: 38755645
[TBL] [Abstract] [Full Text] [Related]
2. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract] [Full Text] [Related]
3. Differentially expressed genes associated with high metabolic tumor volume served as diagnostic markers and potential therapeutic targets for pancreatic cancer.
Kim BG; Lee SH; Jang Y; Kang S; Kang CM; Cho NH
J Transl Med; 2024 May; 22(1):453. PubMed ID: 38741142
[TBL] [Abstract] [Full Text] [Related]
4. Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma.
Kasuga R; Taniki N; Chu PS; Tamura M; Tabuchi T; Yamaguchi A; Hayatsu S; Koizumi J; Ojiro K; Hoshi H; Kaneko F; Morikawa R; Noguchi F; Yamataka K; Usui S; Ebinuma H; Itano O; Hasegawa Y; Abe Y; Kitago M; Inoue M; Nakatsuka S; Jinzaki M; Kitagawa Y; Kanai T; Nakamoto N
Sci Rep; 2024 May; 14(1):10896. PubMed ID: 38740983
[TBL] [Abstract] [Full Text] [Related]
5. Enrichment and Evaluation of Antitumor Properties of Total Flavonoids from
Yang S; Chu G; Wu J; Zhang G; Du L; Lin R
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731467
[TBL] [Abstract] [Full Text] [Related]
6. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of pancreatic Carcinomas: In Search of Therapeutic Targets.
Faber EB; Krause HB; Amin K; Walker P; Hosein PJ; Shields AF; Lenz HJ; Prakash A; Goel S; Oberley M; Malleo G; Luchini C; Hwang J; Florou V; Garrido-Laguna I; Lou E
JCO Precis Oncol; 2024 May; 8():e2300595. PubMed ID: 38723231
[TBL] [Abstract] [Full Text] [Related]
7. Immune checkpoint inhibitor associated diarrhoea.
Al-Hussainy A; Adams J; Simmons J; Kennedy J
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719255
[TBL] [Abstract] [Full Text] [Related]
8. [Analysis of factors affecting the prognosis of patients with pancreatic cancer patients with obstructive jaundice].
Zhang L; Li M; Sun QF; Yu HP
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):474-479. PubMed ID: 38715484
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Zhang P; Chen Z; Shi S; Li Z; Ye F; Song L; Zhang Y; Yin F; Zhang X; Xu J; Cheng Y; Su W; Shi M; Fan S; Tan P; Zhong C; Lu M; Shen L
Cancer Immunol Immunother; 2024 May; 73(7):119. PubMed ID: 38713205
[TBL] [Abstract] [Full Text] [Related]
10. treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract] [Full Text] [Related]
11. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma.
Li F; Si W; Xia L; Yin D; Wei T; Tao M; Cui X; Yang J; Hong T; Wei R
Mol Cancer; 2024 May; 23(1):90. PubMed ID: 38711083
[TBL] [Abstract] [Full Text] [Related]
12. Physical function as a predictor of chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
Lin KY; Chen PS; Lin CF
BMC Gastroenterol; 2024 May; 24(1):154. PubMed ID: 38711006
[TBL] [Abstract] [Full Text] [Related]
13. QbD Enabled Development and Evaluation of Pazopanib Loaded Nanoliposomes for PDAC treatment.
Shinde A; Panchal K; Patra P; Singh S; Enakolla S; Paliwal R; Chaurasiya A
AAPS PharmSciTech; 2024 May; 25(5):97. PubMed ID: 38710894
[TBL] [Abstract] [Full Text] [Related]
14. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
[TBL] [Abstract] [Full Text] [Related]
15. NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors.
Wang Y; Liu X; Zuo X; Wang C; Zhang Z; Zhang H; Zeng T; Chen S; Liu M; Chen H; Song Q; Li Q; Yang C; Le Y; Xing J; Zhang H; An J; Jia W; Kang L; Zhang H; Xie H; Ye J; Wu T; He F; Zhang X; Li Y; Zhou G
Cell Genom; 2024 May; 4(5):100550. PubMed ID: 38697125
[TBL] [Abstract] [Full Text] [Related]
16. Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan.
Takayama K; Kojima A; Honda C; Nakayama M; Kanemata S; Endo T; Muro K
Cancer Med; 2024 May; 13(9):e7170. PubMed ID: 38693813
[TBL] [Abstract] [Full Text] [Related]
17. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for pancreatic cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract] [Full Text] [Related]
18. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
19. Understanding autoimmune pancreatitis: Clinical features, management challenges, and association with malignancies.
Christodoulidis G; Kouliou MN; Koumarelas KE
World J Gastroenterol; 2024 Apr; 30(15):2091-2095. PubMed ID: 38681985
[TBL] [Abstract] [Full Text] [Related]
20. The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat Liver Resection.
Gon H; Komatsu S; Omiya S; Kido M; Fukushima K; Urade T; Yoshida T; Arai K; Ishida J; Nanno Y; Tsugawa D; Yanagimoto H; Toyama H; Fukumoto T
Anticancer Res; 2024 May; 44(5):2031-2038. PubMed ID: 38677757
[TBL] [Abstract] [Full Text] [Related]
[Next]
